Elgene Lim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1468871/publications.pdf

Version: 2024-02-01

106	9,371	76326	42399
papers	citations	40 h-index	92 g-index

122	122	122	17035
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epigenetic Therapies and Biomarkers in Breast Cancer. Cancers, 2022, 14, 474.	3.7	16
2	Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC). Cancer Research, 2022, 82, PD13-07-PD13-07.	0.9	5
3	A new sophistication for breast cancer PDXs. Nature Cancer, 2022, 3, 138-140.	13.2	3
4	Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review. Cancers, 2022, 14, 920.	3.7	10
5	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. Cancers, 2022, 14, 2404.	3.7	2
6	Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones. Cancers, 2022, 14, 2292.	3.7	6
7	64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial. Pharmaceuticals, 2022, 15, 772.	3.8	8
8	A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.. Journal of Clinical Oncology, 2022, 40, 1021-1021.	1.6	15
9	CDK4/6 inhibitor plus endocrine therapy for hormone receptorâ€positive, HER2â€negative metastatic breast cancer: The new standard of care. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-14.	1.1	11
10	The androgen receptor is a tumor suppressor in estrogen receptorâ€“positive breast cancer. Nature Medicine, 2021, 27, 310-320.	30.7	122
11	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. Genes, 2021, 12, 285.	2.4	18
12	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Medicine, 2021, 13, 81.	8.2	25
13	Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.. Journal of Clinical Oncology, 2021, 39, 1020-1020.	1.6	27
14	Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review. Frontiers in Oncology, 2021, 11, 701424.	2.8	7
15	Abstract 129: An integrated multi-omic cellular atlas of human breast cancers. Cancer Research, 2021, 81, 129-129.	0.9	3
16	Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. Npj Breast Cancer, 2021, 7, 111.	5.2	9
17	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nature Communications, 2021, 12, 5112.	12.8	38
18	Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Research, 2021, 23, 82.	5.0	14

#	Article	IF	Citations
19	DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity. Cell Reports, 2021, 36, 109722.	6.4	39
20	A single-cell and spatially resolved atlas of human breast cancers. Nature Genetics, 2021, 53, 1334-1347.	21.4	535
21	The management of HER2â€positive early breast cancer: Current and future therapies. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-12.	1.1	7
22	Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. Cancers, 2021, 13, 4972.	3.7	9
23	Diagnostic value of 68 Gaâ€DOTATATE PETâ€CT imaging for staging of ER + /PR + HER2â€breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18 Fâ€FDG PETâ€CT in a prospective pilot trial. Journal of Medical Imaging and Radiation Oncology, 2021, , .	1.8	3
24	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers, 2021, 13, 5527.	3.7	4
25	MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 777867.	2.8	4
26	Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing. Breast Cancer Research and Treatment, 2021, 191, 501.	2.5	1
27	Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discovery Today, 2020, 25, 406-413.	6.4	140
28	Window of opportunity treatment in breast cancer. ANZ Journal of Surgery, 2020, 90, 34-40.	0.7	2
29	Stromal cell diversity associated with immune evasion in human tripleâ€negative breast cancer. EMBO Journal, 2020, 39, e104063.	7.8	224
30	MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Research, 2020, 22, 87.	5.0	37
31	OR05-06 The Androgen Receptor Is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer. Journal of the Endocrine Society, 2020, 4, .	0.2	0
32	Estrogen receptor positive breast cancer patientâ€“derived xenograft models in translational research. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 31-36.	1.4	1
33	Optimizing care for younger women with hormone receptorâ€positive, HER2â€negative metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 3-14.	1.1	3
34	Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. Breast Cancer Research, 2020, 22, 63.	5.0	8
35	Testosterone therapy considerations in oestrogen, progesterone and androgen receptorâ€“positive breast cancer in a transgender man. Clinical Endocrinology, 2020, 93, 355-357.	2.4	10
36	The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Introduction and Overview. , 2020, , 1-9.		4

#	Article	IF	Citations
37	Testosterone therapy considerations in oestrogen, progesterone and androgen receptorâ€“positive breast cancer in a transgender man. , 2020, 93, 355.		1
38	Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer. Cancer Research, 2020, 80, PD7-05-PD7-05.	0.9	10
39	A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.. Journal of Clinical Oncology, 2020, 38, 1023-1023.	1.6	29
40	Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. Endocrine-Related Cancer, 2020, 27, R93-R112.	3.1	16
41	Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study. Cancer Research, 2020, 80, P5-14-05-P5-14-05.	0.9	1
42	Assessment and management of bone health in women with oestrogen receptorâ€positive breast cancer receiving endocrine therapy: position statement summary. Medical Journal of Australia, 2019, 211, 224-229.	1.7	11
43	The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology. Acta Cytologica, 2019, 63, 257-273.	1.3	71
44	Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes. Cancers, 2019, 11, 682.	3.7	10
45	Estrogen receptor signaling is reprogrammed during breast tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11437-11443.	7.1	55
46	Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Breast Cancer Research, 2019, 21, 43.	5.0	33
47	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. International Journal of Molecular Sciences, 2019, 20, 667.	4.1	19
48	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2019, 174, 271-278.	2.5	31
49	Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocrine-Related Cancer, 2019, 26, R15-R30.	3.1	96
50	Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocrine-Related Cancer, 2019, 26, 251-264.	3.1	29
51	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. EBioMedicine, 2018, 29, 166-176.	6.1	4
52	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nature Medicine, 2018, 24, 463-473.	30.7	120
53	Attitudes of patients with metastatic cancer towards research biopsies. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 231-238.	1.1	1
54	Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 3-11.	1.1	4

#	Article	IF	Citations
55	Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2â€nonâ€amplified metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 12-21.	1.1	1
56	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1385-1393.	10.7	342
57	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications, 2018, 9, 2897.	12.8	293
58	Assessment and management of bone health in women with oestrogen receptorâ€positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clinical Endocrinology, 2018, 89, 280-296.	2.4	24
59	A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. Nature Communications, 2018, 9, 2311.	12.8	104
60	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, R123-R144.	3.1	64
61	Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. Cell Reports, 2017, 18, 2359-2372.	6.4	59
62	Sensitizing HR-proficient cancers to PARP inhibitors. Molecular and Cellular Oncology, 2017, 4, e1299272.	0.7	4
63	Neoadjuvant Interferons: Critical for Effective PD-1â€“Based Immunotherapy in TNBC. Cancer Immunology Research, 2017, 5, 871-884.	3.4	63
64	Secreted Tumor Antigens â€“ Immune Biomarkers for Diagnosis and Therapy. Proteomics, 2017, 17, 1600442.	2.2	27
65	The role of MDM2 and MDM4 in breast cancer development and prevention. Journal of Molecular Cell Biology, 2017, 9, 53-61.	3.3	56
66	Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology, 2016, 6, 7.	2.8	266
67	Pushing estrogen receptor around in breast cancer. Endocrine-Related Cancer, 2016, 23, T227-T241.	3.1	35
68	Renewed interest in the progesterone receptor in breast cancer. British Journal of Cancer, 2016, 115, 909-911.	6.4	28
69	Adjuvant endocrine therapy in women with oestrogenâ€receptorâ€positive breast cancer: how should the skeletal and vascular side effects be assessed and managed?. Clinical Endocrinology, 2016, 85, 689-693.	2.4	9
70	EMT, cell plasticity and metastasis. Cancer and Metastasis Reviews, 2016, 35, 645-654.	5.9	672
71	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports, 2016, 17, 2367-2381.	6.4	215
72	IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG. Oncogene, 2016, 35, 1111-1121.	5.9	51

#	Article	IF	Citations
73	MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. Cancer Discovery, 2016, 6, 45-58.	9.4	57
74	A laminin 511 matrix is regulated by TAZ and functions as the ligand for the Î±6Bî²1 integrin to sustain breast cancer stem cells. Genes and Development, 2015, 29, 1-6.	5.9	131
75	Adjuvant Chemotherapy in Breast Cancer. , 2015, , 335-351.		0
76	Targeting the Androgen Receptor in Breast Cancer. Current Oncology Reports, 2015, 17, 4.	4.0	86
77	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell, 2015, 163, 174-186.	28.9	346
78	IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Communications, 2015, 6, 8746.	12.8	125
79	Abstract P3-05-14: Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer. , 2015, , .		0
80	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. ELife, 2014, 3, e01763.	6.0	104
81	Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy. Current Breast Cancer Reports, 2014, 6, 71-78.	1.0	13
82	XBP1 promotes triple-negative breast cancer by controlling the HIF1Î± pathway. Nature, 2014, 508, 103-107.	27.8	663
83	PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombinationâ€“Mediated DNA Repair. Cancer Discovery, 2014, 4, 1430-1447.	9.4	125
84	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell, 2014, 26, 222-234.	16.8	71
85	Protein Kinase C Î± Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells. Cancer Cell, 2013, 24, 347-364.	16.8	277
86	The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor. Cancer Cell, 2013, 24, 365-378.	16.8	120
87	PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells. Cancer Cell, 2013, 23, 753-767.	16.8	56
88	Amplitude modulation of androgen signaling by c-MYC. Genes and Development, 2013, 27, 734-748.	5.9	78
89	Breast Cancer in Adolescents and Young Adults: A Review With a Focus on Biology. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1060-1069.	4.9	59
90	Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition.. , 2013, , .		3

#	Article	IF	Citations
91	Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases.. , 2013, , .		0
92	Sensitization of BCL-2â€“expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2766-2771.	7.1	173
93	Ï°B Kinase Îµ Phosphorylates TRAF2 To Promote Mammary Epithelial Cell Transformation. Molecular and Cellular Biology, 2012, 32, 4756-4768.	2.3	56
94	Elucidating the role of androgen receptor in breast cancer. Clinical Investigation, 2012, 2, 1003-1011.	0.0	11
95	The natural history of hormone receptor-positive breast cancer. Oncology, 2012, 26, 688-94, 696.	0.5	70
96	Adjuvant chemotherapy in luminal breast cancers. Breast, 2011, 20, S128-S131.	2.2	15
97	Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer. Cancer Cell, 2011, 20, 119-131.	16.8	340
98	Will preoperative trials change future clinical practice?. Clinical Investigation, 2011, 1, 59-73.	0.0	1
99	ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics, 2010, 26, 2176-2182.	4.1	463
100	Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Research, 2010, 12, R21.	5.0	354
101	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 2009, 15, 907-913.	30.7	1,261
102	OPTIMIZING THE APPROACH TO PATIENTS WITH POTENTIALLY RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER. ANZ Journal of Surgery, 2007, 77, 941-947.	0.7	5
103	Diagnosing cancer: changing patterns of care. Internal Medicine Journal, 2007, 37, 124-126.	0.8	1
104	Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. Melanoma Research, 2006, 16, 347-355.	1.2	14
105	The influence of language spoken on colorectal cancer diagnosis and management. ANZ Journal of Surgery, 2006, 76, 671-672.	0.7	7
106	Subsite-Specific Colorectal Cancer in Diabetic and Nondiabetic Patients. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1579-1582.	2.5	13